IP Library Granted Patent US 8,809,323
Granted Patent B2
US 8,809,323 · App. 13/896,876 · Granted Aug 19, 2014

Therapeutic applications of pro-apoptotic benzodiazepines

Inventors: Gary D. Glick (Ann Arbor, MI); Anthony W. Opipari, Jr. (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan
C07D243/14A61K31/55A61K31/5513C07D403/12C07D243/24C07D401/12A61K31/551C07D413/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,809,323
App. No.
13/896,876
Granted
Aug 19, 2014
Kind
B2
Abstract

Benzodiazepine compounds, and methods for using those compounds are provided. Some of the benzodiazepine compounds include 1,4-benzodiazepine-2-one and 1,4-benzodiazepine-2,5-dione compounds of structures: wherein R 1 , R 2 , R 3 and R 4 are as defined. The invention also includes enantiomers, pharmaceutically acceptable salts, prodrugs or derivatives of the benzodiazepine compounds. Any one or more of these benzodiazepine compounds can be used to treat a variety of dysregulatory disorders related to cellular death. Such disorders include autoimmune disorders, inflammatory conditions, hyperproliferative conditions, viral infections, and atherosclerosis. In addition, the above compounds can be used to prepare medicaments to treat the above-described dysregulatory disorders. The benzodiazepines can also be used in drugs screening assays and other diagnostic methods.

Claims (16)

1. A method of treating a disorder selected from the group consisting of an autoimmune disorder, a hyperproliferative disorder, a chronic inflammatory condition, and atherosclerosis, comprising administering an effective amount of a benzodiazepine compound to a subject suffering from said autoimmune disorder, said hyperproliferative disorder, or said chronic inflammatory condition, wherein said benzodiazepine compound is represented by:

or an enantiomer or pharmaceutically acceptable salt thereof, wherein:

R 1 is aliphatic;

R 2 is

R 3 is hydrogen or an aliphatic group having 1-8 carbons and 1-20 hydrogens; and

R 4 is halogen.

2. The method of claim 1 , wherein R 1 is methyl.

3. The method of claim 1 , wherein R 3 is hydrogen.

4. The method of claim 1 , wherein the benzodiazepine compound is the following:

or a pharmaceutically acceptable salt thereof.

5. The method of claim 1 , wherein the disorder is an autoimmune disorder selected from the group consisting of graft versus host disease, rheumatoid arthritis, and systemic lupus erythematosus.

6. The method of claim 1 , wherein the disorder is rheumatoid arthritis.

7. The method of claim 1 , wherein the disorder is asthma.

8. The method of claim 1 , wherein the disorder is Crohn's disease.

9. The method of claim 1 , wherein the disorder is psoriasis.

10. The method of claim 1 , wherein the disorder is a chronic inflammatory condition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2013
From: GLICK, GARY D.; OPIPARI, ANTHONY W., JR.
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 030448/0835 →
Continuity (7)
Continuation 11807046 · May 25, 2007
Continuation 11585492 · Oct 23, 2006
Continuation 09700101
Provisional Application 60191855 · Mar 24, 2000
Provisional Application 60131761 · Apr 30, 1999
Provisional Application 60165511 · Nov 15, 1999
Related Publication 20140038947A1 · Feb 6, 2014